Han Xiangming, Wang Qiyan, Fang Sheng, Wang Jialin, Liu Fusheng, Zhang Junwen, Jin Guishan
Brain Tumor Research Center, Beijing Neurosurgical Institute, Beijing Laboratory of Biomedical Materials, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China.
Front Oncol. 2022 Apr 13;12:836511. doi: 10.3389/fonc.2022.836511. eCollection 2022.
Glioblastoma multiforme (GBM) is a common intracranial malignancy characterized by abundant and aberrant vasculature. The efficiency of existing antivascular treatments remains unsatisfactory. The transition of glioblastoma stem-like cells (GSCs) into tumor endothelioid cells (ECs) has been thought to cause glioma neovascularization and anti-angiogenesis tolerance, but the mechanisms regulating glioma transdifferentiation remains unclear. Our previous study found that P4HA1 regulates GSCs vascular mimicry in a hypoxic microenvironment, but the detailed molecular mechanism has not been determined. In this study, candidate protein COL6A1 was screened by mass spectrometry. experiments show that P4HA1 regulates the expression of CD31 COL6A1, with the levels of expression of P4HA1, COL6A1 and the vascular endothelial molecular markers CD31 showing positive correlations assay. Altering the expression of P4HA1 in GSCs altered the expression of COL6A1 and CD31, thereby inducing glioma angiogenesis. In conclusion, this study revealed that the P4HA1/COL6A1 axis modulates the transdifferentiation process of GSCs into ECs. Interrupting this signaling axis can inhibit glioma angiogenesis, suggesting that this axis may be a novel target for antivascular therapy in patients with glioma.
多形性胶质母细胞瘤(GBM)是一种常见的颅内恶性肿瘤,其特征是具有丰富且异常的血管系统。现有的抗血管生成治疗效果仍不尽人意。胶质母细胞瘤干细胞(GSCs)向肿瘤内皮样细胞(ECs)的转变被认为会导致胶质瘤新生血管形成和抗血管生成耐受,但调节胶质瘤转分化的机制仍不清楚。我们之前的研究发现,P4HA1在缺氧微环境中调节GSCs的血管拟态,但具体分子机制尚未确定。在本研究中,通过质谱筛选出候选蛋白COL6A1。实验表明,P4HA1调节CD31和COL6A1的表达,P4HA1、COL6A1和血管内皮分子标志物CD31的表达水平呈正相关。改变GSCs中P4HA1的表达会改变COL6A1和CD31的表达,从而诱导胶质瘤血管生成。总之,本研究揭示了P4HA1/COL6A1轴调节GSCs向ECs的转分化过程。中断该信号轴可抑制胶质瘤血管生成,表明该轴可能是胶质瘤患者抗血管生成治疗的新靶点。